By the PharmaTradz BD Team. Published October 2026.
Good Distribution Practice (GDP) is the set of quality rules that keeps a medicine safe and genuine after it leaves the factory. It covers buying, storing, transporting, supplying and exporting medicines, so that the product a pharmacy or hospital receives is exactly as good as the one the manufacturer released. GMP makes the product right; GDP keeps it right until it reaches the patient.
In pharma, GDP applies to wholesalers, importers, third-party warehouses, transport companies and brokers. If you import, distribute or tender for medicines, it is the standard you and your logistics partners will be inspected against.
GDP vs GMP: where one ends and the other begins
Good Manufacturing Practice (GMP) covers how a medicine is made, tested and released. Once a batch is certified and leaves the manufacturer's site, the risks change. The product can be stored too hot, mixed up with returned stock, delayed in customs, stolen, or swapped for a fake. GDP is designed for those risks.
| GMP | GDP | |
|---|---|---|
| Main question | Was the product made correctly? | Has its quality and identity been kept intact since release? |
| Who it applies to | Manufacturers, packagers, testing laboratories | Wholesalers, importers, warehouses, transport providers, brokers |
| Typical licence | Manufacturing authorisation | Wholesale distribution authorisation |
| Key person | Qualified Person (QP) releases each batch in the EU | Responsible Person (RP) oversees the distribution quality system |
| Main risks | Contamination, mix-ups, process errors | Temperature excursions, damage, diversion, falsified products, wrong customer |
| Main EU text | EudraLex Volume 4 | EU GDP Guidelines (2013/C 343/01) |
The two overlap. A manufacturer that ships its own product must follow GDP for those activities, and a distributor that repacks or relabels may need a manufacturing authorisation because that work counts as manufacturing.
The main GDP guidelines
EU GDP Guidelines (2013/C 343/01)
The European Commission's Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use, published as 2013/C 343/01, are the reference text most companies work to. They are based on Article 84 and Article 85b(3) of Directive 2001/83/EC and replaced an earlier version from March 2013. They have ten working chapters plus final provisions:
| Chapter | What it covers |
|---|---|
| 1. Quality management | A documented quality system, change control, corrective and preventive action (CAPA) and management review |
| 2. Personnel | The Responsible Person, other key staff, training and hygiene |
| 3. Premises and equipment | Warehouses, segregation, temperature mapping, calibration, computerised systems |
| 4. Documentation | Procedures and records, kept clear and retrievable |
| 5. Operations | Qualifying suppliers and customers, receipt, storage, picking, supply, export |
| 6. Complaints, returns, suspected falsified medicines and recalls | How each is handled, recorded and reported |
| 7. Outsourced activities | Written contracts and oversight of warehouses and carriers you use |
| 8. Self-inspections | Regular internal audits against GDP |
| 9. Transportation | Keeping storage conditions in transit, handling deviations, containers and labelling |
| 10. Specific provisions for brokers | Brokers who arrange sales without handling the product |
A separate EU text, the Guidelines of 19 March 2015 on principles of Good Distribution Practice of active substances (2015/C 95/01), applies to companies that distribute APIs rather than finished medicines.
WHO GDP
The World Health Organization's guidance is Good storage and distribution practices for medical products, published in 2020 as Annex 7 of WHO Technical Report Series No. 1025. It combines storage and distribution in one document and adds quality risk management, management review and a section on substandard and falsified products. Many national regulators outside Europe base their rules on it.
PIC/S PE 011
The PIC/S Guide to Good Distribution Practice for Medicinal Products (PE 011-1) came into force on 1 June 2014. It closely follows the EU text in nine chapters, with EU-specific references removed. The brokers chapter is left out, imports are covered alongside exports, and it refers to "designated responsible persons" rather than a single Responsible Person. It is not binding on its own; each member authority decides how to adopt it. India's CDSCO has also published GDP guidelines for consultation, so check your own regulator's current text.
US DSCSA, briefly
The United States has no single GDP guideline of the EU kind. Distribution is controlled through state wholesaler licensing and the Drug Supply Chain Security Act (DSCSA), enacted in 2013. DSCSA requires trading partners to exchange transaction data, trade only with authorised partners, and quarantine and investigate suspect products. Prescription drug packages carry a product identifier in a 2D barcode. Electronic, package-level tracing became required from 27 November 2023, followed by a one-year stabilisation period to 27 November 2024. FDA then gave staged exemptions, ending on 27 May 2025 for manufacturers and repackagers, 27 August 2025 for wholesale distributors and 27 November 2025 for large dispensers. Dispensers with 25 or fewer pharmacists and pharmacy technicians have until 27 November 2026.
Key GDP requirements
A licence. In the EU, anyone who procures, holds, supplies or exports medicines needs a wholesale distribution authorisation. Inspectors may then issue a GDP certificate, which is listed in the EU's EudraGMDP database.
A Responsible Person. Each authorised wholesaler names an RP who keeps the quality system working. The EU text says a degree in pharmacy is desirable. The RP approves suppliers and customers, decides what happens to returned or suspect stock, and coordinates recalls. The RP should be continuously contactable and may delegate duties but not responsibility.
Qualified suppliers and customers. Stock may only come from holders of a wholesale or manufacturing authorisation, and the distributor must check that its supplier follows GDP. Medicines may only be supplied to other authorised wholesalers or to people entitled to supply the public, such as pharmacies and hospitals. These checks are repeated periodically. Unusual sales patterns, especially for products open to misuse, should be investigated.
Temperature mapping and monitoring. Before a storage area is used, it is mapped under representative conditions to find hot and cold spots. Monitoring probes are then placed where the mapping showed the biggest swings. Mapping is repeated after significant changes to the building or equipment, or when a risk assessment calls for it. Monitoring devices are calibrated at defined intervals.
Transport qualification. Storage conditions must be kept during transport. Routes are risk-assessed, and qualified equipment such as insulated packaging or temperature-controlled vehicles is used where needed. This is often called transport validation. Excursions must be reported to the distributor and the recipient and investigated. Monitoring equipment in vehicles and containers should be calibrated at least once a year. For fridge and freezer products, our explainer on the pharma cold chain covers ranges and excursions in detail.
Falsified-medicine controls. A suspected falsified product must be physically segregated in a dedicated area, and the competent authority and the marketing authorisation holder must be told immediately. In the EU, most prescription medicines also carry safety features under Delegated Regulation (EU) 2016/161, applied since 9 February 2019: a unique identifier in a 2D barcode and an anti-tampering device. Our guide to verifying suppliers and avoiding counterfeits covers the buyer's side.
Returns and recalls. Returns are assessed under a written, risk-based procedure. Stock can go back to saleable inventory only if it is unopened, undamaged, in date, not recalled and returned within an acceptable time limit. The EU text gives 10 days as an example for returns from customers without a wholesale licence. Temperature-sensitive returns need proof they were stored correctly throughout. Recall arrangements must work quickly, and their effectiveness is tested regularly.
What a GDP warehouse looks like
A compliant warehouse is clean, dry, secure and access-controlled, with pest control and enough space to keep stock orderly. Separate, clearly marked areas hold quarantined, rejected, returned, recalled and suspected falsified stock. Receiving and dispatch bays protect goods from the weather. Stock is rotated on first expired, first out (FEFO), and expired stock is removed from saleable inventory. Controlled drugs, flammables and high-risk products need extra safeguards. Computerised stock systems are validated so that the records can be trusted. The product's labelled storage conditions come from its stability data, which our explainer on stability testing explains.
A worked example
An importer receives 500 cartons of an antibiotic labelled "Store below 25°C". On receipt, staff check the delivery note against the order, inspect the cartons for damage, and download the shipment's data logger. The logger shows four hours at 31°C while the container sat at the port. Under GDP, the importer quarantines the whole delivery, records the excursion, and informs the supplier. The marketing authorisation holder then assesses the excursion against its stability data. The Responsible Person releases the stock only if that assessment shows quality is unaffected. If the same lane keeps producing excursions, the importer changes its packaging or route and records the action as a CAPA.
What to check in a logistics partner
If you outsource storage or transport, you remain responsible. EU GDP requires a written contract that sets out each party's duties, and you should audit the partner before and during the contract. Useful questions:
- Does the partner hold a wholesale distribution authorisation or the licence your market requires, and a recent GDP certificate or inspection report?
- Who is its Responsible Person, and how is that person reached out of hours?
- Can it show temperature mapping reports for the areas your stock will use, and calibration records for its probes?
- How are alarms and excursions handled at night and at weekends, and how quickly will you be told?
- What transport qualification data covers your routes and seasons, including packaging and vehicles?
- Does it use subcontractors, and does it audit them?
- How are returns, recalls and suspected falsified products segregated and recorded?
- Can it run a mock recall and trace a batch to every customer within hours?
- Do you get batch-level stock reports and access to its records for your own audits?
Setting up an import business from scratch? Our guide on starting a pharmaceutical import business covers the licences you will need.
How PharmaTradz can help
We connect importers and distributors with manufacturers and service providers that can support GDP-compliant supply. Our cold chain pharma logistics service covers temperature-controlled shipping. Tell us the product, storage conditions and destination, and send us an RFQ. For other terms, see our pharma abbreviations A-Z.
Frequently Asked Questions(FAQs)
What is the full form of GDP in pharma?
GDP stands for Good Distribution Practice. It is the part of quality assurance that makes sure medicines keep their quality and identity while they are bought, stored, transported and supplied after leaving the manufacturer.
What is the difference between GMP and GDP?
GMP covers how a medicine is made, tested and released by the manufacturer. GDP takes over after release and covers wholesalers, warehouses, importers and transport, so the product reaches the patient in the same condition.
What are the EU GDP guidelines?
They are the European Commission's Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (2013/C 343/01). They have ten chapters plus final provisions, covering quality management, personnel, premises, documentation, operations, returns and recalls, outsourcing, self-inspection, transport and brokers.
Who is the Responsible Person in GDP?
The Responsible Person is the named individual at a licensed wholesaler who makes sure the GDP quality system works. In the EU they approve suppliers and customers, decide on returned and suspect stock, and coordinate recalls.
Is temperature mapping required under GDP?
Yes. EU GDP requires an initial temperature mapping of a storage area before use, with monitoring probes placed where the mapping shows the greatest fluctuation. Mapping is repeated after significant changes or when a risk assessment calls for it.
